A prospective, population-based study of 40,000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma
International Journal of Cancer,

Nielsen K et al. – Our study supports divergent etiologic pathways to CM, with high numbers of nevi correlated to increased risk for trunk CM. Furthermore, it confirms that high numbers of nevi, red hair and heredity for CM are the most important risk factors and frequent sunbed use might be a risk factor for younger women.

Methods

  • Host factor- and UVR exposure data were collected prospectively by questionnaire in this population-based cohort study including 40,000 Swedish born women, aged 25–64 years at enrolment (1990).
  • Risk for CM (Cox regression and Stepwise Cox regression [SCR], hazard ratios [HRs] with 95% Confidence Intervals [CI]) in relation to risk factors, age groups (older or younger than 40 years) and primary site, were analyzed. In 29,520 women with complete follow-up through 2007, 155 invasive and 60 insitu CM were recorded.

Results
  • High numbers of nevi (HR, 2.9; 95% CI, 1.7–5.0) and heredity (HR, 3.7; 95% CI, 2.0–6.8) were associated with risk for CM.
  • SCR analysis added red hair as a risk factor.
  • Sunbed use >10 times/year increased risk for women <40 years (HR, 2.5; 95% CI, 1.0–6.2) and a trend for risk associated with sunbathing vacations (HR, 1.4; 95% CI, 1.0–2.0) was shown for women >40 years.
  • Trunk melanoma showed correlations with high numbers of nevi (HR, 3.0; 95% CI, 1.2–7.3) and heredity (HR, 3.2; 95% CI, 1.1–9.4).
  • Head/neck site was correlated to sunbathing vacations (HR, 2.5; 95% CI, 1.2–5.3) and heredity (HR, 7.6; 95% CI, 1.8–31.8).

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...

    Currently, there are no available articles.

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Coffee intake and gastric cancer risk Cancer Epidemiology, Biomarkers & Prevention, March 20, 2014    Clinical Article

2 The dirty side of soap UC San Diego Health System, November 20, 2014

3 Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: The Cancer-DACUS Study Journal of Clinical Oncology, October 10, 2014    Clinical Article

4 Molecular breakthrough could halt the spread of prostate cancer University of Bristol Research News, November 14, 2014

5 Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial The Lancet Oncology, November 10, 2014    Clinical Article

6 Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer European Journal of Cancer, August 6, 2014    Clinical Article

7 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 23, 2014    Clinical Article

8 Metformin in chemotherapy-naive castration-resistant prostate cancer: A multicenter phase 2 trial (SAKK 08/09) Full Text European Urology, August 15, 2014    Free full text    Clinical Article

9 New insight on oral cancer culprits Vanderbilt University Medical Center Research News, November 17, 2014

10 Coffee plus honey versus topical steroid in the treatment of chemotherapy-induced oral mucositis: A randomized controlled trial Full Text BMC Complementary and Alternative Medicine, August 28, 2014    Free full text    Clinical Article

11 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 30, 2014    Clinical Article

12 Serum copper is a simple but valuable prognostic marker in B-cell chronic lymphocytic leukemia International Journal of Hematology, October 24, 2014    Clinical Article

13 Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer Journal of Clinical Oncology, November 19, 2014    Clinical Article

14 Phase II trial of the anti-CD19 bispecific T cell–engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia Journal of Clinical Oncology, November 17, 2014    Clinical Article

15 Smoking associated with elevated risk of developing a second smoking-related cancer American Society of Clinical Oncology (ASCO) News, November 12, 2014

16 Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial The Lancet Oncology, October 6, 2014    Clinical Article

17 Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia New England Journal of Medicine, June 4, 2014    Evidence Based Medicine    Clinical Article

18 Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Annals of Oncology, November 21, 2014    Clinical Article

19 Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer Annals of Oncology, November 4, 2014    Clinical Article

20 Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: A meta-analysis Clinical Cancer Research, November 17, 2014    Evidence Based Medicine

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore